Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0268318 (ICP)
 10,007 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Antiserum to ICP 10, a herpes simplex virus type 2 (HSV-2) protein that is expressed in cells neoplastically transformed by viral DNA sequences within the Bgl II/Hpa I CD fragment, specifically precipitates the ICP 10 protein from HSV-2 infected cells and stains cells infected with HSV-2 for 4 to 16 hrs by indirect immunofluorescence. At 4 hr post infection (p.i.), the staining is primarily perinuclear, while at 16 hr p.i., it is cytoplasmic and intranuclear. Compartmentalization studies indicate that the 35S-[L]-methionine labeled ICP 10 is detectable in both the cytoplasmic and nuclear fractions early and late in infection. However, in its phosphorylated form, ICP 10 is undetectable in the nuclear fraction late in the viral reproductive cycle. Anti-ICP 10 serum stains a high (75%-83%) proportion of cervical tissue with pathological findings of dysplasia or carcinoma, as well as atypical exfoliated cells from these patients. Cervical tumor tissue from 4 of 12 patients also stains with antiserum to another purified viral protein complex designated ICP 12/14. In the majority of atypical cells with mild or moderate changes, ICP 10 localizes in the cytoplasm, while the majority of atypical cells with severe changes also display nuclear staining with anti-ICP 10 serum. While exfoliated atypical cells from 60% of patients with dysplasia are positive for ICP 10, those from only one half of these patients stain also with anti-ICP 12/14 serum and this staining is strictly cytoplasmic. Atypical cells from three patients in these series stain with the anti-HSV-2 serum but are negative for both ICP 10 and ICP 12/14. Exfoliated atypical cells from patients with CIS or invasive cancer stain equally well with all three antisera.
Cancer Invest 1983
PMID:Expression and cellular compartmentalization of a herpes simplex virus type 2 protein (ICP 10) in productively infected and cervical tumor cells. 632 Sep 93

The studies associating infections by herpes simplex virus type 2 (HSV-2) with carcinoma of the human uterine cervix are reviewed within the context of three possible interpretations. Extensive seroepidemiologic evidence indicates that the virus does not grow preferentially in neoplastic tissue, nor is the association of HSV-2 with cervical carcinoma a reflection of their independent relationship to promiscuity. While a number of infectious agents, including other viruses, are associated with cervical atypia, only HSV-2 is a significant risk factor for CIS. In vitro transformation data supporting the oncogenic potential of the virus are summarized, and evidence is presented that an antigen designated ICP 10/AG-4 is a valid candidate for the role of a virus-encoded protein involved in the maintenance of a transformed phenotype. Antibody to AG-4 is IgM, and it is detected by microquantitative complement fixation. With this assay, it is demonstrated that conversion to anti-AG-4 occurs during primary infection with HSV-2; however, it is transient. In testing 1325 patients, a correlation was observed between antibody to AG-4 and cervical carcinoma. Thus, whereas only 11.7% of controls and 7.7% of patients with cancer at other sites are AG-4 seropositive, as many as 49.6% of patients with dysplasia, 63% of those with CIS, and 72.7% of those with invasive cancer are positive for the antibody. Antibody to AG-4 is related to tumor growth. This is evidence by 1) retrospective analyses demonstrating that the proportion of AG-4 seropositive individuals is directly correlated to the state of the disease and 2) prospective study of 209 patients demonstrating loss of antibody in patients with a successfully removed tumor mass and reappearance of AG-4 antibody in cancer recurrence. The possible use of AG-4 (or its antibody) in the diagnosis and monitoring of cervical carcinoma and its treatment is discussed.
Cancer 1981 Jul 15
PMID:Viruses and gynecologic cancers: herpesvirus protein (ICP 10/AG-4), a cervical tumor antigen that fulfills the criteria for a marker of carcinogenicity. 702 62

Searching for bladder cancer, 1268 flow-through-cytophotometric determinations of DNA in nuclei of cells were done using the ICP 11. 134 urines (36.2%) and 15 bladder washings (2.9%) could not be evaluated. The examination of urines led to a right positive diagnosis in 56.7%. The corresponding values in wash-out material and biopsy specimen were 61.2% and 75.3%. False positive results were found of 32.5% of the urines, 6.2% of the wash-out fluid and 9.1% in the biopsy specimens. The results are slightly less advantageous than those of conventional cytodiagnostic. Using a special way in selecting the results, false positive values could be eliminated. By this the tentative diagnosis of cancer gained by flow-through-cytophotometry, could be estimated to be correct in a high percentage. It seems that the flow-through-cytophotometry carried out as additional morphological test is an improvement in diagnosis and grading as well as in estimating prognosis and therapeutic results of urological cancer.
 ...
PMID:[Automatic cytodiagnostic of bladder cancer (author's transl)]. 704 58

Flow-through cytophotometric DNA determinations with the ICP 11 were carried out in nuclei of testes stained with ethidium bromide. The histograms of healthy testicles showed two haploid peaks (1 CI/1CII), a diploid (2C) and a tetraploid peak (4C). The more spermatogenesis was histologically reduced, the more the height of the haploid and tetraploid peaks and of the graph in the area of the S-phase was decreased. It resulted from a relative increase of diploid cells of testicular parenchyma. Conclusions can be drawn from the DNA histogram on the degree of inhibition of spermatogenesis, but not on its etiology (inflammation, malposition, endocrime disorders). In torsions of tests, the histogram showed differences from normal graphs, increasing with the degree of necrosis. The histograms of malignant tumors of testes had many more signals in the area of the S-phase and in the hypertetraploid region than those of testes without malignant tumors. In addition, they all had aneuploid peaks, although not in each of the multiple samples of one tumor. Nonseminomas differed more from tumor-free testes than did seminomas. The DNA determinations in nuclei of testes gave objective information about spermatogenesis and, in torsions of testes, about the rate of necrosis. It facilitated the intraoperative decision as to whether a testis should be conserved or extirpated. Malignancy could be established with a high degree of certainty. The difference between histograms of testicular carcinomas and healthy testes seemed to give prognostic information.
 ...
PMID:The prognostic power of flow-through cytophotometric DNA determinations for testicular diseases. 746 99

Element concentrations in ribs obtained from elderly Japanese people (17 males and 28 females; mean age, 81.5 years) were determined by atomic absorption spectrometry (AAS), inductively coupled plasma atomic emission spectrometry (ICP-AES), and ICP mass spectrometry (ICP-MS). Nine elements--Na, Mg, P, K, Ca, Fe, Zn, Sr, and Pb--were determinable in most of the subjects by a combination of AAS and ICP-AES. The levels of these elements were generally comparable with those obtained in our previous study on ribs from younger Japanese. By the use of ICP-MS, Sn (median, 0.79 micrograms/g dry bone) and Ba (1.3 micrograms/g) were determinable in all of the subjects analysed (n = 35) and 18 other elements at lower concentration levels were also detected in some of the subjects. An exploratory statistical analysis was carried out to find element(s) of which level(s) in rib vary in the presence of degenerative chronic diseases, using information obtained from pathological autopsy reports and medical histories of the present subjects. It indicated that (i) Pb and Zn, (ii) Ba, and (iii) Sr levels in the ribs varied in the presence of cancer, cerebrovascular damage, and bone problems, respectively. The present results were discussed in relation to the results of the previous epidemiologic and experimental studies.
 ...
PMID:Trace elements in ribs of elderly people and elemental variation in the presence of chronic diseases. 789 57

The use of ICP-MS and its various sample introduction techniques has great potential in extending the time scale of study for the pharmacokinetics of platinum containing anti-tumour drugs. Electrothermal vaporization ICP-MS can be used to measure very small samples with very low concentrations. Speciation studies of platinum in tissues can be carried out with HPLC-ICP-MS over longer time periods. Finally, LA-ICP-MS is potentially useful for studying the spatial distribution of platinum in tissues and tumours.
Cancer Surv 1993
PMID:New techniques in the pharmacokinetic analysis of cancer drugs. II. The ultratrace determination of platinum in biological samples by inductively coupled plasma-mass spectrometry. 813 50

Copper (Cu) accumulating in the liver of LEC (Long-Evans with a cinnamon-like coat color) rats due to a hereditary metabolic disorder is assumed to cause acute hepatitis with severe jaundice or chronic hepatitis leading to cancer. Changes in concentrations and distributions of Cu, zinc and iron in the liver of LEC rats were determined to find the relationship between the chemical forms and the toxicity. Female rats after delivery were used because of high susceptibility to acute hepatitis. They were divided into four stages according to the development of jaundice. Cu concentrations in the whole liver and the supernatant decreased with development of jaundice. Distribution profiles of Cu, zinc, iron and sulfur on a gel filtration column by HPLC-ICP showed that Cu in the liver supernatant was mostly bound to metallothionein (MT) before jaundice (stage 1), high molecular weight proteins and MT at the beginning of jaundice (stages 2 and 3), and then mostly to MT at severe jaundice (stage 4) though the concentration of Cu at this stage was decreased to about 50% of stage 1. The results suggest that Cu accumulating as MT in the liver is liberated drastically after exceeding the capacity of MT synthesis, and the liberated Cu causes acute hepatitis.
 ...
PMID:Changes in hepatic copper distribution leading to hepatitis in LEC rats. 830 89

Modified, nonneurovirulent herpes simplex viruses (HSVs) have shown promise in the treatment of brain tumors. However, HSV-1 can infect and lyse a wide range of cell types. In this report, we show that HSV-1716, a mutant lacking both copies of the gene coding ICP-34.5, can effectively treat a localized i.p. malignancy. Human malignant mesothelioma cells supported the growth of HSV-1716 and were efficiently lysed in vitro. i.p. injection of HSV-1716 into animals with established tumor nodules reduced tumor burden and significantly prolonged survival in an animal model of non-central nervous system-localized human malignancy without dissemination or persistence after i.p. injection into SCID mice bearing human tumors. These findings suggest that this virus may be efficacious and safe for use in localized human malignancies of nonneuronal origin such as malignant mesothelioma.
Cancer Res 1997 Feb 01
PMID:Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. 901 75

Modified, non-neurovirulent herpes simplex viruses (HSV) have shown promise for the treatment of brain tumors, including intracranial melanoma. In this report, we show that HSV-1716, an HSV-1 mutant lacking both copies of the gene coding-infected cell protein 34.5 (ICP 34.5), can effectively treat experimental subcutaneous human melanoma in mice. In vitro, HSV-1716 replicated in all 26 human melanoma cell lines tested, efficiently lysing the cells. Therapeutic infection of subcutaneous human melanoma nodules with HSV-1716 led to viral replication that was restricted to tumor cells by immunohistochemistry. Moreover, HSV-1716 treatment significantly inhibited progression of preformed subcutaneous human melanoma nodules in SCID mice and caused complete regression of some tumors. This work expands the potential scope of HSV-1-based cancer therapy.
 ...
PMID:Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. 918 25

Platinum-DNA adducts can be assayed in peripheral blood leukocytes by means of atomic absorption spectroscopy and ELISA, and high adduct levels have been correlated previously with favorable clinical response to platinum-based chemotherapy. Our purpose was to study adduct formation in peripheral blood leukocytes by means of a new method, inductively coupled plasma mass spectroscopy (ICP-MS), and to correlate adduct formation with clinical response and toxicity. Platinum (Pt)-DNA adducts were measured by means of ICP-MS in leukocytes of 66 patients receiving a cisplatin- or carboplatin-based chemotherapy, collected either before the beginning of treatment and incubated in vitro with cisplatin or 1 and 24 h after the administration of drug to the patient. The Pt-DNA adduct level in leukocytes from patients exposed to drug in vitro was 14.33 +/- 14.71 fmol/microgram DNA (mean +/- SD), which was not significantly different from the value of 23.4 +/- 19.53 fmol/microgram DNA observed in leukocytes from nine healthy volunteers. In samples collected after the administration of chemotherapy, Pt-DNA adducts ranged from 1.91 +/- 3.59 fmol/microgram DNA (mean +/- SD) at the 1-h time point to 2.61 +/- 3.35 fmol/microgram DNA at 24 h (P > 0.05). Adduct levels in leukocytes exposed in vitro did not correlate with adduct levels from patients treated with cisplatin-based chemotherapy (r = 0.085 and 0.011 at 1 and 24 h, respectively). At 24 h, adduct levels in patients receiving cisplatin (3.15 +/- 3.64 fmol/microgram DNA, mean +/- SD) were significantly higher (P = 0.02) than those observed in patients treated with standard dose carboplatin (0.57 +/- 0.73 fmol/microgram DNA) and also higher than those in patients receiving high-dose carboplatin (1.18 +/- 1.06 fmol/microgram DNA), although the latter difference did not reach statistical significance (P = 0.071). No differences in adduct levels (mean +/- SD) were evident between patients responsive (3.23 +/- 3.51 fmol/microgram DNA) and nonresponsive (2.34 +/- 3.01 fmol/microgram DNA) to chemotherapy. In the homogeneous group of patients treated with combination of cisplatin and 5FU, received dose intensity, hemoglobin decrease, and posttreatment creatinine could not be linked with the extent of leukocyte adduct formation. The data presented here demonstrate that ICP-MS allows the detection of adducts in patients treated with cisplatin or carboplatin and suggest that adduct formation in leukocytes is not a major determinant of response or toxicity.
Clin Cancer Res 1996 Nov
PMID:Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. 981 37


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>